News & Events

New CDC Guidelines Recognize Value of Split Septum IV Access Technology to Reduce Intravascular Catheter-Related Bloodstream Infections

BD Q-Syte™ Luer Access Split Septum Device Proven to Improve Patient Safety

Contact: Alyssa Zeff
Corporate Communications
(201) 847-4358

Sandy, UT (April 4, 2011) – BD Medical, a segment of BD (Becton, Dickinson and Company), announced today that new guidelines from the Centers for Disease Control and Prevention (CDC) for healthcare workers and hospitals demonstrate that the technology used in the BD Q‑Syte™ Luer Access Split Septum catheter may help reduce intravascular catheter-related bloodstream infections.

About 30,000 people a year die in the United States every year because of catheter-related bloodstream infections, according to the CDC.  The new guidelines state, “When needleless systems are used, a split septum valve may be preferred over some mechanical valves due to increased risk of infection with the mechanical valves.”

The CDC recommendations, created by the Healthcare Infection Control Practices Advisory Committee (HICPAC), cite recent peer-reviewed studies that support the use of split-septum devices over mechanical valves. According to a study published in the December 2009 issue of Clinical Infectious Disease, strong evidence demonstrates that mechanical valve needleless connectors are associated with an increase in bloodstream infections (BSIs), despite similar BSI surveillance and prevention strategies.

“The new guidelines from the CDC represent a major milestone in providing effective and efficient ways to reduce CR-BSIs,” said Dr. William Jarvis, MD, president of Jason and Jarvis Associates, LLC, a private consulting company in healthcare epidemiology and infection control, as well as former president of the Society for Healthcare Epidemiology of America (SHEA) and former acting director of the CDC’s Hospital Infection Program.  “It is important for healthcare professionals and hospitals to consider following these guidelines to not only reduce rates of CR-BSIs, but also to improve overall patient safety and reduce healthcare costs.”

The BD Q-Syte™ Luer Access Split Septum is a true split-septum device with a design that can make a significant impact reducing CRBSIs. In fact, when compared to mechanical valves, split-septum devices have shown 64-70 percent lower CR-BSI rates. Split-septum devices have the ability to eliminate the complexities of mechanical valves as well as the bacteria they may harbor.

“BD has long recognized the impact that split septum needleless connectors may have on reducing infections,” said William A. Kozy, BD Executive Vice President.  “We applaud the CDC for giving healthcare providers clear direction on how to protect their patients from preventable infections.”

The CDC reports that of the 99,000 healthcare-associated infections (HAI)-related deaths per year, approximately 30,000 of them are caused by BSIs. Additionally, with more than 80,000 occurrences in the U.S. ICUs, CR-BSIs result in $29 billion in annual treatment costs. With the Center for Medicare and Medicaid Services (CMS) and major insurance carriers discontinuing increased payment for hospital-associated CR-BSIs, it is more critical than ever for hospitals to adopt best practices to reduce such infections.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit